Using rTMS guided by MEG to treat migraines
Prospective Exploratory Study on rTMS for Migraine Under the Guidance of MEG
NA · Ruijin Hospital · NCT06796725
This study is testing whether a new treatment using brain stimulation can help people with migraines feel better compared to a standard medication.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 15 Years to 50 Years |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06796725 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) guided by magnetoencephalography (MEG) in treating migraine patients. Participants will be randomly assigned to receive either the rTMS treatment or the traditional medication Sibelium. The study will assess clinical efficacy based on headache frequency, severity, duration, and analgesic use, while also analyzing genetic correlations with treatment outcomes. The goal is to explore innovative approaches for migraine management.
Who should consider this trial
Good fit: Ideal candidates are adults experiencing frequent migraines, occurring at least 15 days per month, who have not found relief with traditional medications.
Not a fit: Patients under 15 years old or those with specific eye conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, non-invasive option for migraine relief.
How similar studies have performed: Other studies have shown promise in using rTMS for migraine treatment, but this specific approach using MEG is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Complies with specific disease diagnosis: A. Headaches that meet the criteria of B and C (headaches that meet the characteristics of tension headaches or migraines) should occur at least 15 days per month and last for at least 3 months; B. Headaches that meet the criteria of 1.1 migraine without aura diagnosis B-D or 1.2 migraine with aura B and C occurring at least 5 times; C. Headache meets any of the following criteria and occurs for more than 8 days per month, lasting for more than 3 months: ①1.1 C and D of migraine without aura②1.2 B and C of migraine with aura③ The migraine attack perceived by the patient can be relieved by taking triptan or ergot, which cannot be better explained by other diagnoses in ICHD-3. * Must be able to swallow tablets * Signed and dated informed consent form Promise to comply with research procedures and cooperate in implementing the entire research process Exclusion Criteria: * Age under 15 years old; Accompanied by optic disc edema, focal symptoms and signs of the nervous system (except for typical visual and sensory precursors) or cognitive impairment; Sudden and rapidly peaking severe headaches (thunderous headaches) * Accompanied by fever; New onset headaches in adults, especially after the age of 50; Headaches in patients with high coagulation risk * New headache in patients with tumor or AIDS history; Headaches related to changes in body position; * History of epileptic seizures
Where this trial is running
Shanghai
- Ruijin Hospital — Shanghai, China (RECRUITING)
Study contacts
- Study coordinator: Xiaodan Wang, Doctor
- Email: wxd12466@rjh.com.cn
- Phone: +86-21-64370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Migraine Disorders, Brain, rTMS Stimulation, Migraine, MEG, rTMS, RCT